NCT04491682View on ClinicalTrials.gov

Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Atypical Endometrial Hyperplasia
Interventions
DRUG

Megestrol Acetate

At a dosage of 160 mg/day

DRUG

Rosuvastatin

At a dosage of 10 mg/day

Trial Locations (1)

Unknown

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04491682 - Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia | Biotech Hunter | Biotech Hunter